key: cord-0763441-8xlcm3t2
authors: Baruchel, André; Bertrand, Yves; Boissel, Nicolas; Brethon, Benoit; Ducassou, Stéphane; Gandemer, Virginie; Halfon-Domenech, Carine; Leblanc, Thierry; Leverger, Guy; Michel, Gérard; Petit, Arnaud; Ray-Lunven, Anne-France; Rohrlich, Pierre-Simon; Schneider, Pascale; Sirvent, Nicolas; Strullu, Marion
title: COVID19 and acute lymphoblastic leukemias of children and adolescents: first recommendations of the Leukemia committee of the French Society for the fight against Cancers and Leukemias in children and adolescents (SFCE)
date: 2020-04-30
journal: Bull Cancer
DOI: 10.1016/j.bulcan.2020.04.003
sha: 00ec6e927034a7b70159a09a6e54b74d08ac03c8
doc_id: 763441
cord_uid: 8xlcm3t2

Abstract Since the emergence of the SARS-CoV-2infection, many recommendations have been made. However, the very nature of acute lymphoblastic leukemias and their treatment in children and adolescents led the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE) to propose more specific recommendations, even if data for this population are still scarce. They may have to evolve according to the rapid evolution of knowledge on COVID19.

COVID19 and acute lymphoblastic leukemias of children and adolescents: first recommendations of the Leukemia committee of the French Society for the fight against Cancers and Leukemias in children and adolescents (SFCE) It is necessary to insist on the need, in particular in the regions with high prevalence, to "over-isolate" a child or adolescent COVID-negative to allow him to securely advance in the treatment (facial mask, barrier measures, no contact with suspect COVID or COVID + for 3 weeks ...), in particular those intended to be allografted.

Are you changing your approach to initial induction?

There is a controversy about the use of steroids, a key part of induction therapy.

If the physician considers that the patient is at high risk of complications, we recommend a multidisciplinary discussion and / or with the coordinators of the protocol with a view to considering reductions in dose or in the number of administrations of certain drugs including potentially steroids. Once all the induction chemotherapy has been administered, the use of G-CSF in a COVID + patient can be discussed to reduce the duration of neutropenia.

The implementation of all or part of treatment on an outpatient basis must be carefully weighed. Indeed, the comings and goings to the ambulatory clinic and blood samplings at home increase the number of contacts at risk. Conversely, return at home could limit contact with caregivers, also possibly contaminated.

In most hospitals, visits are limited to only parents, with only one parent present at a time.

Note that the risk of needing an intensive care bed during induction therapy is low (probably <5%). However, in certain regions, the decrease in the number of pediatric ICU beds (transformed into adult resuscitation beds) implies that the pediatric need is being forcefully re-expressed.

a. Philadelphia chromosome ALL: some adult hematologists (see ASH adult ALL COVID19 recommendation) offer treatment with a tyrosine kinase inhibitor with minimal steroid exposure rather than aggressive induction with multidrug therapy for the initial treatment, in the hope of avoiding prolonged hospitalization during the pandemic. However, the recommendation to include our patients in the EsPhall 2017 protocol seems appropriate to us.

b. Infants under one year of age: the risk of serious forms of COVID19 in infants has been reported. The test for SARS-CoV-2, possibly repeated, is absolutely necessary here. Again, the recommendation is to follow the current guidelines i.e. to follow the Interfant 06 protocol.

c. Adolescents and young adults: take into account the risk factors observed in adults, asthma, obesity, diabetes. Insist on compliance with treatment in general but also on that linked to containment measures and barrier gestures.

d. Children with Down syndrome: vigilance is essential in these children susceptible to infections in general, even if this susceptibility rarely concerns viral infections. Of note this group benefits from an induction with "only" 3 drugs in the CAALL-F01 protocol.

In the absence of data, our recommendation is to follow the protocol, including for corticosteroid therapy.

For patients with high-risk ALL, an individualized decision regarding transplantation and its timing is necessary, weighing the risks of transplantation in an epidemic context of COVID-19 against the risk linked to ALL.

Three problems are mainly to be discussed :

-Intensity of maintenance treatment with 6MP / MTX and targets for leukocytosis / neutrophils / lymphocytes: we suggest to follow the usual recommendations of the protocol.

-pulses : monthly pulses (CAALL-F01, B-SR group) or every 10 weeks (CAALL-F01, B-MR group) with vincristine and steroids are to be maintained. COVID19 testing the day before could be useful if feasible: if COVID +, then postpone the pulse for about 2 weeks.

-High dose methotrexate cycles in maintenance for T-ALL with high initial leucocyte count (≥ 100 G/L) and/or CNS3 status : any concern could be discussed with the protocol coordinators.

In addition, minimizing hospital visits seems appropriate. Monitor patients as much as possible via telemedicine and home blood tests.

-First relapse: we propose to include all eligible patients and to follow the INTREALL protocol as much as possible. Patients who reach complete remission n°2 should be considered promptly for allogeneic transplantation, as indicated in the protocol, despite the pandemic.

-Second relapse and refractory relapses :

• Phase I-II trials: it is likely that almost all academic or industrial promoters will ask for SARS-Co-V2 testing before inclusion and that any positivity will be an exclusion criterion, at least temporarily.

• CAR-T cells: The indication for treatment with CAR-T cells must be weighed with the center which would perform them: feasibility of performing apheresis (systematic patient testing, problem of using an operating room for the special catheter placement for example)? Manufacturing feasibility? Feasibility of administration according to the possible places in intensive care unit ?

General recommendations

1. The diagnosis of SARS-CoV-2 infection during the treatment of ALL should imply to discuss the stopping and / or postponing of all chemotherapies, according to the severity of the ALL, the stage of treatment and the severity of clinical and / or radiological signs. Even if severe forms have been recently described, most of the experience is currently reassuring (2-4) 2. Any "specific" treatment must be discussed with the infectious disease team.

They are described in Table 1 aiming to list some of the treatments with antiviral potential and some of those proposed to act against the inflammatory process. Of note, the inflammatory stage of covid19 infection is generally the one of aggravation, and often involves hospitalization in ICU. Chemotherapy is obviously interrupted at this stage.

These recommendations have to be updated in the future with more experience and more data gathered at the national and international level and in the evolving context of the pandemic and the weapons to combat it.

(Version 1.0; last update 20.04. 2020)

Références Table 1 Page 

SARS-CoV-2 Infection in Children

Flash Survey on SARS-CoV-2 Infections in Pediatric Patients on anti-Cancer Treatment

Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hemato-oncology center embedded within a COVID-19 dedicated hospital in

Pertuisel S et al for the Société Française de lutte contre les Cancers et leucémies de l'Enfant et de l'adolescent (SFCE). COVID-19 in pediatric oncology from French pediatric oncology and hematology centers: high-risk of severe forms? Pediatr Blood Cancer